These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 21209031)

  • 1. Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome.
    Luque-Ramírez M; Álvarez-Blasco F; Alpañés M; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2011 Mar; 96(3):846-52. PubMed ID: 21209031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
    Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of circulating hepcidin in association with iron excess, metabolic syndrome, and BMP-6 expression in granulosa cells in women with polycystic ovary syndrome.
    Kim JW; Kang KM; Yoon TK; Shim SH; Lee WS
    Fertil Steril; 2014 Aug; 102(2):548-554.e2. PubMed ID: 24875397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is hepcidin a new cardiovascular risk marker in polycystic ovary syndrome?
    Gözdemir E; Kaygusuz I; Kafalı H
    Gynecol Obstet Invest; 2013; 75(3):196-202. PubMed ID: 23548757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron metabolism and the polycystic ovary syndrome.
    Escobar-Morreale HF
    Trends Endocrinol Metab; 2012 Oct; 23(10):509-15. PubMed ID: 22579050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations.
    Luque-Ramírez M; Escobar-Morreale HF
    Horm Metab Res; 2010 Oct; 42(11):815-20. PubMed ID: 20730705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients.
    Luque-Ramírez M; Alvarez-Blasco F; Escobar-Morreale HF
    Obesity (Silver Spring); 2009 Jan; 17(1):3-9. PubMed ID: 18997670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.
    Hendy OM; Allam M; Allam A; Attia MH; El Taher S; Eldin MM; Ali A
    Egypt J Immunol; 2010; 17(2):33-44. PubMed ID: 23082485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin.
    Ruivard M; Lainé F; Ganz T; Olbina G; Westerman M; Nemeth E; Rambeau M; Mazur A; Gerbaud L; Tournilhac V; Abergel A; Philippe P; Deugnier Y; Coudray C
    J Hepatol; 2009 Jun; 50(6):1219-25. PubMed ID: 19398238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
    Luque-Ramírez M; Mendieta-Azcona C; del Rey Sánchez JM; Matíes M; Escobar-Morreale HF
    Eur J Endocrinol; 2009 Mar; 160(3):469-80. PubMed ID: 19139031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of serum hepcidin and iron levels in patients with PCOS: a case-control study.
    Hossein Rashidi B; Shams S; Shariat M; Kazemi Jaliseh H; Mohebi M; Haghollahi F
    J Endocrinol Invest; 2017 Jul; 40(7):779-784. PubMed ID: 28276006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
    Ibáñez L; de Zegher F
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D; De Cicco S; Tagliaferri V; Proto C; Lanzone A; Guido M
    J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients.
    Kebapcilar L; Kebapcilar AG; Bilgir O; Taner CE; Bozkaya G; Yildiz Y; Sari I
    Gynecol Endocrinol; 2011 Feb; 27(2):91-5. PubMed ID: 20528207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome.
    Escobar-Morreale HF; Luque-Ramírez M
    Fertil Steril; 2011 Apr; 95(5):1730-5.e1. PubMed ID: 21300335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.